Literature DB >> 12172240

Revision ossicular reconstruction with the titanium Kurz prosthesis.

Brian W Downs1, James M Pearson, Carlton J Zdanski, Craig A Buchman, Harold C Pillsbury.   

Abstract

OBJECTIVE/HYPOTHESIS: One European multicenter study has reported favorable outcomes after ossicular reconstruction with the titanium Kurz prosthesis. At the time of this study, however, no study has analyzed its outcomes when used for reconstruction after prior failure with another implant (revision reconstruction). The study reports our experience with the titanium Kurz prosthesis for revision ossicular reconstruction. STUDY
DESIGN: A retrospective review was made of all revision ossicular reconstructions at our institution from October 1998 to September 2001.
METHODS: Seventeen cases were reviewed. Patients were divided into two groups: patients who underwent revision ossicular reconstruction with the Kurz prosthesis and patients who underwent revision ossicular reconstruction with another prosthesis (the "other" group). Audiograms were reviewed and air-bone gaps were calculated for each patient.
RESULTS: The average postoperative air-bone gap after Kurz revision was 15.6 dB, a statistically significant improvement over the average postoperative air-bone gap from the "other" revision group (P =.022).
CONCLUSION: The titanium Kurz prosthesis has been an effective implant at our institution for revision ossicular reconstruction. Future research should focus on a prospective, randomized trial comparing the Kurz prosthesis with other prostheses currently in use.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12172240     DOI: 10.1097/00005537-200208000-00002

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  1 in total

1.  Hearing results with the titanium ossicular replacement prostheses.

Authors:  Sébastien Schmerber; Joelle Troussier; Georges Dumas; Jean-Pierre Lavieille; Dinh-qui Nguyen
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-12-03       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.